S Medicare Advantage members whove end stage renal disease.

Aetna companions with Fresenius HEALTH CARE to improve lives of people with end stage renal disease Fresenius Medical Care and Aetna announced today a collaborative treatment model designed to improve the quality of care for Aetna's Medicare Advantage members who’ve end stage renal disease, while lowering healthcare costs. Fresenius HEALTH CARE North America's nationally-recognized care management plan is accredited by the National Committee for Quality Assurance, and creates a new approach for the overall delivery of caution focused squarely on the initial needs of dialysis patients http://genericsildenafil.org . Through this collaboration, Aetna nurse case managers will work closely with FMCNA staff on quality and care administration for Aetna Medicare Benefit members who are receiving treatment at an FMCNA clinic.

The analysis is conducted under a Cooperative Research and Development Contract between Aeterna Zentaris and the Michael E. DeBakey Veterans Affairs Medical Center which is funding the study. Jose M. Duncan Cancers Center and the Huffington Center on Aging at Baylor College of Michael and Medicine E. Juergen Engel, PhD, President and CEO of Aeterna Zentaris stated, This is an integral study as it we can venture into the field of cancer-cachexia, a sign with high unmet medical needs. Because cachexia is very common among cancer sufferers, our oral ghrelin agonist, AEZS-130, could represent a novel treatment choice for many of the 1.S.